Coherus BioSciences' Q4 Sales Fall 34% On Lower Udenyca Volume, Prices


Coherus BioSciences Inc's CHRS Q4 net revenue was $73.4 million for Q4 FY21 compared to $110.4 million for the same period in 2020, missing estimates of $85.81 million.

  • The decline was primarily due to a decrease in the number of units of Udenyca sold and a reduction in net realized price due to increased competition and COVID-19 impacts.
  • The company posted an adjusted EPS loss of $(0.46), beating the consensus of $(0.51).
  • During the quarter, FDA approved Yusimry (adalimumab-aqvh), a Humira biosimilar. Coherus plans the U.S. launch of Yusimry after July 1, 2023, per the terms of an agreement with AbbVie Inc ABBV.
  • Related: Coherus' Udenyca Body Injector At par With Pre-filled syringe.
  • "In 2022, we expect to launch two new products, if approved, including our first immuno-oncology antibody, toripalimab, addressing an unmet need in nasopharyngeal carcinoma, as well as CIMERLI," said Denny Lanfear, CEO.
  • Coherus projects combined R&D and SG&A expenses in 2022 to be $415 million - $450 million, excluding a potential $25 million milestone payable upon FDA approval of the toripalimab for nasopharyngeal carcinoma and the $35 million exercise the option for the license to JS006, which is expected to close in Q1 FY22.
  • Price Action: CHRS shares closed lower by 2.50% at $12.85 on Thursday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!